MAPK9, mitogen-activated protein kinase 9, 5601

N. diseases: 115; N. variants: 1
Disease: Malignant Neoplasms ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE PARP-14 has recently appeared to be involved in the transduction pathway mediated by JNKs (c Jun N terminal Kinases), among which JNK2 promotes cancer cell survival. 31130919 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE We suggest restoring p-JNK2 expression as a novel therapeutic strategy to early prevent the development of UC-related cancer. 28383667 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Additionally, siRNA-mediated JNK2 knockdown blocked docetaxel-induced HIF-1α degradation and cancer cell death by inhibiting PHD1 activation. 27263528 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 Biomarker group BEFREE Their anticancer mechanisms of action, after binding to specific receptors on cancer cells, include targeting the Rat sarcoma-bound guanosine triphosphate (RAS) (95% inhibition)-mitogen activated protein kinase kinase 1/2 (MEK-1/2) (98% inhibition)-extracellular signal-related kinases 1/2 (ERK-1/2) (96% inhibition) cascade in cancer cells.They also inhibit MAPK9, i.e. c-JUN-N-terminal kinase 2. 24692673 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.050 AlteredExpression group BEFREE The expression of the JNK-1 and JNK-2 is frequently elevated in breast cancer and is a frequent genetic abnormality in this malignancy. 20878129 2010